News articles about Chiasma (NASDAQ:CHMA) have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Chiasma earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 47.0834701549871 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Separately, ValuEngine upgraded Chiasma from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st.

Shares of Chiasma (NASDAQ CHMA) opened at $1.90 on Monday. Chiasma has a 52-week low of $1.25 and a 52-week high of $2.95.

In related news, Director Scott Minick purchased 15,000 shares of Chiasma stock in a transaction on Wednesday, September 20th. The shares were purchased at an average price of $2.38 per share, for a total transaction of $35,700.00. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 3.80% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Chiasma (CHMA) Receives Daily Coverage Optimism Score of 0.08” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/11/20/chiasma-chma-receives-daily-coverage-optimism-score-of-0-08.html.

Chiasma Company Profile

Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.

Insider Buying and Selling by Quarter for Chiasma (NASDAQ:CHMA)

Receive News & Stock Ratings for Chiasma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma Inc. and related stocks with our FREE daily email newsletter.